VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolut... (isk factors is contained in VaxGen's Ann...)

VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.

Date:5/4/2008

isk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. VaxGen Issues Rebuttal to MedCap Letter
3. VaxGen Common Stock Now Quoted on OTC Bulletin Board
4. VaxGen Reports Financial Update
5. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
8. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
9. VaxGen Addresses MPM Claims in Letter to Stockholders
10. VaxGen Files Last Outstanding Periodic Report With SEC
11. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals

Post Your Comments:

(Date:11/20/2009)... METTLER TOLEDO recently announce...rocess Optimization Using At-Line Particle Charact... 2009. In this webinar, the application of in sit... the design space and optimize a series of roller ...rates, and roller compaction forces. , ...

(Date:11/19/2009)... people would like to be able to charge their cell... not too often. A recent discovery made by UC San ...d supercapacitors that could do just this. , In...tters , Prabhakar Bandaru, a professor in the UCSD...g, along with graduate student Mark Hoefer, have f...

(Date:11/19/2009)..., SEATTLE, Nov. 19 Omer...audited financial results for the third quarter en... September 30, 2009, Omeros reported a net loss of...a net loss of $7.4 million, or $2.54 per share, fo...ed September 30, 2009, the Company reported a net ...

(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-...), an innovator in biotechnology for diabetes ther...nsulting services to food, supplement, biotechnolo...t closed the previously reported $6.3 million regi... of 2,760,870 shares of its common stock and warra...

Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2 Nanotube defects equal better energy and storage systems 2 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8 Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2 Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3

[0] Roller Compaction Process Optimization Using At-Line Particle Characterization [0] Nanotube defects equal better energy and storage systems [0] Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights [0] Spherix Announces the Closing of $6.3 Million Registered Direct Offering

...ngboard for Growth in 2009 and ... international,seed brands serve as an ideal launc...es of biotechnology traits with significant scale ...utive vice president of global,commercial, will te...al,Chemicals Conference in New York., Begemann wi...

...eering (NYSE: AOB ) announced today that it has w... The decision to cancel its,convertible preferred ...,prevailing market conditions resulting in terms t...arding Forward-Looking Statements, Statements mad...e made,pursuant to the safe harbor provisions of t...

...oration (Nasdaq: CSCX ), a global leader in advan...n, and informatics products, announced today,that ...mpany Biotechnology,and Medical Technology Confere... senior vice president and chief financial officer...recent financial results during the,Company,s pres...

Other Biology Technology:Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 2 Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 3 Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 4 Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference 2

Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America American Oriental Bioengineering Announces that it Withdraws Convertible Preferred Stock Offering Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference

(Date:11/20/2009)... research report published in the November 2009 is...s.org ), scientists show how a family of genes (1-...enes) are responsible for production of ethylene. ..., and this information lays the foundation for fut...sease resistant, able to survive and thrive in dif...

(Date:11/20/2009)...g highly precise measurements of plasma lipoprotei...sonance spectroscopy (NMR), researchers led by Dan...rvard Medical School in Boston, MA, the Framingham...ortium in Stockholm, Sweden and Oxford, England pe...ole genome among 17,296 women of European ancestry...

(Date:11/20/2009)...archers are invited to contribute their abstracts ...O ECCEO10), the largest global meeting devoted to...search and patient care. The Congress will be held...ing today, abstracts can be submitted online at h...deadline is February 4, 2010. , IOF and ESCEO ar...

[0] It's a gas: New discovery may lead to heartier, high-yielding plants [0] Genetic analysis helps dissect molecular basis of cardiovascular disease [0] Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10

...University of California, Riverside has used chemi...ct the ability of plants to alter their direction ...wn as gravitropism. , The researchers screened a l...known as chemical genomics, to identify those that...ffect on plant growth, which is closely linked to ...

...be any major relief this spring or summer from the...acific Northwest, according to new projections of ...general circulation" models that forecast global c...earchers at the U.S.D.A. Forest Service and Oregon...n part of the country will face forest and rangela...

... a single protein is critical in the cellular expo...is, researchers report in the March issue of Cell ...n every 200 to 300 people in Western populations -...ith iron. Left untreated, the hereditary disease c...researchers at the Children,s Hospital Boston and ...

Other Biology News:Researchers discover chemical compounds that affect plant growth 2 No relief for Pacific Northwest drought 2 No relief for Pacific Northwest drought 3 Iron exporter revealed that may explain common human disorder 2 Iron exporter revealed that may explain common human disorder 3

Researchers discover chemical compounds that affect plant growth No relief for Pacific Northwest drought Iron exporter revealed that may explain common human disorder

Rocking table Kick II from Sigma-Aldrich

PROTEAN II xi Multi-Cell 2-D Conversion Kit from Bio-Rad

SVT3-2 Diverter Valve from Bio-Rad

...or vertical electrophoresis applications. The cell....2 L of running buffer. It includes the PROTEAN II...which contains accessories for use with 2.0 mm thi...of 20 x 20 cm glass plates, 4 IPG spacers, 2 IPG c...

Biology Products:

Rocking table Kick II from Sigma-Aldrich PROTEAN II xi Multi-Cell 2-D Conversion Kit from Bio-Rad SVT3-2 Diverter Valve from Bio-Rad PROTEAN II XL Cell, wide format, 2.0 mm from Bio-Rad

VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolut...(isk factors is contained in VaxGen's Ann...)